The ultrasound therapeutics developer, a University of Oxford spinout, has raised series B2 funding in the run-up to clinical testing of its cancer drug delivery platform.
OxSonics Therapeutics, a UK-based ultrasound cancer drug delivery technology spinout of University of Oxford, has completed an oversubscribed £10.5m ($13.1m) series B2 round with undisclosed new and existing investors.
Founded in 2013, OxSonics is working on a technology called SonoTrans intended to bolster the efficacy of existing cancer drugs.
SonoTrans exploits an approach called inertial cavitation in which ultrasound is used to form bubbles capable of penetrating deeper into cancerous tumours.
The series B2 cash will go…
